Veritas Genetics Acquires Curoverse
August 3, 2017
Veritas Genetics has acquired Boston-based Curoverse, the creator of the Arvados open-source genomic data platform, for an undisclosed amount. The acquisition brings Curoverse’s bioinformatics, data-management and AI/ML capabilities in-house to expand Veritas’s capacity for large-scale genome interpretation and deploy machine learning across millions of genomes.
- Buyers
- Veritas Genetics
- Targets
- Curoverse
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
TMX Group Acquires Verity from Resurgens Technology Partners
October 1, 2025
Data & Analytics
TMX Group has acquired Verity, a research management software and data analytics platform, from Resurgens Technology Partners. The deal brings Verity's research workflow and data capabilities — used by more than 300 institutional investors — into TMX Datalinx to expand TMX's investment-grade data, insights and workflow tools for asset managers and other institutional clients.
-
Vividion Therapeutics Acquires Tavros Therapeutics
January 12, 2025
Biotechnology
Vividion Therapeutics, a wholly owned subsidiary of Bayer AG, has acquired precision oncology platform company Tavros Therapeutics. The acquisition expands Vividion’s functional genomics and genomic screening capabilities, combining Tavros’s platform with Vividion’s chemoproteomics expertise to accelerate discovery of novel targets in oncology and immunology; financial terms were not disclosed.
-
Vizgen Acquires Ultivue (Merger to Form Combined Spatial Biology Company)
October 9, 2024
Biotechnology
Vizgen and Ultivue have merged to create a single spatial biology company that combines Vizgen’s MERFISH single-cell spatial genomics platform with Ultivue’s InSituPlex assays and STARVUE proteomic/AI capabilities. Rob Carson (former CEO of Ultivue) will serve as President and CEO of the combined Vizgen, and the transaction was completed alongside Vizgen’s Series D financing backed by investors including ARCH Venture Partners, Northpond Ventures and Tao Capital Partners.
-
Veracyte to Acquire C2i Genomics to Add Whole-Genome MRD Capabilities
January 8, 2024
Healthcare Services
Veracyte has reached a definitive agreement to acquire C2i Genomics, a minimal residual disease (MRD) detection company, to add whole-genome MRD capabilities to its diagnostics platform. Under the terms, Veracyte will pay $70 million in Veracyte shares at closing and up to an additional $25 million tied to future performance milestones, expected to close in the first quarter of 2024.
-
LetsGetChecked Acquires Veritas Genetics and Veritas Intercontinental
March 29, 2022
Healthcare Services
LetsGetChecked announced it will acquire Veritas Genetics Inc. and Veritas Intercontinental to integrate whole genome sequencing and expanded genomic services into its at‑home diagnostics and virtual care platform. The deal adds capabilities across prenatal, predictive medicine, pharmacogenomics and cancer screening and positions LetsGetChecked to expand genomic offerings internationally.
-
Novartis Acquires Vedere Bio
September 30, 2020
Biotechnology
Novartis has acquired Vedere Bio, a Cambridge-based optogenetics AAV gene therapy company, for $150 million upfront plus up to $130 million in potential regulatory and clinical milestones (total consideration of $280 million). The deal includes Vedere Bio's lead preclinical intravitreal AAV programs focused on pan-genotypic vision restoration; earlier-stage assets were spun out into a newly formed independent company, Vedere Bio II.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.